If you’ve spent any time in the peptide research space, you’ll know that GHK-Cu, BPC-157, and TB-500 are three of the most studied compounds in tissue repair and regeneration science. GLOW 70mg brings all three together in a single research stack — and the mechanistic case for combining them is strong.

Here’s what the literature says about each component, and why researchers are increasingly interested in how they work together.

GHK-Cu — The Copper Peptide

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding peptide found in human plasma, saliva, and urine. Levels decline significantly with age — from around 200ng/mL at age 20 to roughly 80ng/mL by age 60 — a drop that coincides with the well-documented deterioration in the body’s capacity for tissue repair and regeneration.

In preclinical research, GHK-Cu has demonstrated a remarkable range of biological activity. Studies have shown it stimulates collagen and elastin synthesis, promotes wound healing, activates antioxidant defence systems, and upregulates genes associated with tissue remodelling. It has also shown anti-inflammatory properties, reducing the production of pro-inflammatory cytokines in damaged tissue.

What makes GHK-Cu particularly interesting from a research perspective is its gene-regulatory reach. Studies using genome-wide analysis have found it capable of modulating the expression of over 4,000 human genes — many associated with inflammation, collagen production, and cellular repair.

BPC-157 — The Systemic Healer

BPC-157 (Body Protective Compound 157) is a synthetic 15-amino acid peptide derived from a protein found in gastric juice. It has become one of the most widely studied peptides in the repair and recovery space, with a substantial body of preclinical research documenting its effects across multiple tissue types.

Animal studies have shown BPC-157 accelerates healing of tendons, ligaments, muscle, bone, and gut tissue. Its mechanisms include upregulation of growth hormone receptors, promotion of angiogenesis (new blood vessel formation), and modulation of the nitric oxide system — all pathways relevant to tissue repair and inflammation resolution.

Notably, BPC-157 has demonstrated a strong safety profile across preclinical studies, with no observed toxicity even at high doses in animal models. It is stable in human gastric juice, which has made it a subject of interest for both systemic and localised research applications.

TB-500 — Flexibility, Recovery, and Systemic Reach

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide present in virtually all human and animal cells. Its primary research interest lies in its ability to promote actin polymerisation — a fundamental process in cell migration, tissue repair, and wound closure.

In preclinical studies, TB-500 has shown significant effects on healing of cardiac tissue, tendons, ligaments, and skin. It also demonstrates anti-inflammatory properties and has been investigated for its role in promoting angiogenesis and neuronal repair. One of its distinguishing characteristics is its systemic reach — research suggests TB-500 can exert effects at sites distant from the injection point, making it a candidate for whole-body repair applications.

Why Stack Them?

Each of these peptides targets overlapping but distinct aspects of the repair and regeneration cascade. GHK-Cu works at the gene-expression level to drive collagen synthesis and remodelling. BPC-157 accelerates multi-tissue healing through growth factor and nitric oxide pathways. TB-500 promotes cell migration and systemic tissue repair via actin regulation.

Together, they represent a broad-spectrum approach to the biology of repair — one that addresses the inflammatory, structural, and regenerative phases simultaneously. Researchers investigating skin health, connective tissue repair, and systemic recovery are increasingly designing protocols that combine these three compounds for precisely this reason.

A Note on Research Use

Australian Peptides supplies GLOW 70mg strictly for research purposes. All products are intended for laboratory and scientific investigation only and are not approved for human therapeutic use in Australia. Findings referenced in this article are drawn from preclinical research. Results observed in animal models may not directly translate to human outcomes.